WHO ICTRP trial
Bioequivalence study of 300 mg ursodeoxycholic acid capsules
IRCT20230222057495N5 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20230222057495N5 |
|---|---|
| Public title | Bioequivalence study of 300 mg ursodeoxycholic acid capsules |
| Scientific title | Bioequivalence study of 300 mg ursodeoxycholic acid capsule of Kimidaro Pharmaceutical Company compared to 300 mg ursodeoxycholic acid of Aurobindo Pharma LTD, India on healthy volunteers |
| Primary sponsor | Chemidarou Pharmaceutical Company |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | In the present study, no disease was investigated.. |
| Interventions | Intervention 1: Intervention group 1: includes the oral consumption of two 300 mg ursodeoxycholic acid capsules manufactured by Kimidarou Pharmaceutical Company of Iran on 24 healthy fasting volunteers. 5 ml of blood at intervals of one and… |
| Registration date | Jun 5, 2023 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: